The Trump administration "will take a look" after billionaire investor Peter Thiel said the FBI and CIA should see if Chinese intelligence has infiltrated Google.Technologyread more
On Monday, the first day of Amazon's 48-hour shopping extravaganza this year, retailers that make more than $1 billion in annual revenues saw a 64% increase in their digital...Retailread more
Builder confidence for single-family homes rose just one point to 65 in July, according to the National Association of Home Builders/Wells Fargo Housing Market Index (HMI)....Real Estateread more
The Federal Reserve's expected interest rate cuts appears to have impacted J.P. Morgan's forecast for 2019 net interest income.Financeread more
Expectations for lower interest rates and less fear about tariffs sent investors back into the market and set up what could be a profitable run ahead.Marketsread more
A crop of long-awaited technology companies coming to the public market this year created a "frothy" period, Bernstein said on TuesdayInvestingread more
GE hasn't had a year this good during this millennium. After that massive surge, one trader is warning investors to stay away.Trading Nationread more
Credit card sales volume rose 11% this quarter and merchant processing volume increased 12%, the bank says in its earnings statement.Banksread more
EU Competition Commissioner Margrethe Vestager is preparing to launch a full probe into Amazon in the coming days, Bloomberg reported.Technologyread more
IBM announced Tuesday that it signed a multi-year agreement with AT&T enabling the carrier to host its business applications on the IBM Cloud.Technologyread more
Amazon Prime Day enters its second day, with more than 1 million deals being offered, including intermittent "lightning deals." Here's how to navigate the 48-hour shopping...Invest in You: Ready. Set. Grow.read more
Acadia Pharmaceuticals shares plunged 22 percent Wednesday after a report the Food and Drug Administration will re-examine its only drug.
Nuplazid, which treats hallucinations and delusions from psychosis associated with Parkinson's disease, has been scrutinized for reports of people dying while taking it. Lawmakers grilled Commissioner Scott Gottlieb in a hearing about why the agency approved the drug and what it would take to have it removed from the market.
Gottlieb told members of Congress he would "take another look" at Nuplazid, CNN reports. The FDA told CNN this week it began conducting a new evaluation of the drug several weeks ago, before Gottlieb was questioned about it.
The drug was first approved in 2016.
An FDA spokeswoman confirmed to CNBC the agency is conducting an evaluation of available information about Nuplazid. An Acadia spokesman referred to the FDA's statement, which noted the review does not mean the FDA has determined the drug has a new risk and the agency does not suggest doctors stop prescribing it and patients stop taking it.
Acadia's stock has plummeted 56 percent over the past year.